Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/57—Nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

• This invention relates to (substituted-aralkyl)- heterocyclic compounds, and in particular relates to such compounds which are useful as inhibitors of the enzyme aromatase.
• Aromatase is an enzyme which effects aromatisation of ring A in the metabolic formation of various steroid hormones.
• Various cancers for example breast cancer, are dependent upon circulating steroid hormones which have an aromatic ring A.
• Such cancers can be treated by removing the source of ring A aromatised steroid hormones, for example by the combination of oophorectomy and adrenalectomy.
• An alternative way of obtaining the same effect is by administering a chemical compound which inhibits the aromatisation of the steroid ring A, and the compounds of the invention are useful for this purpose.
• a variety of compounds possessing aromatase inhibitory activity is known, of which the most important clinically is aminoglutethimide.
• Aminoglutethimide however, has the drawback that it affects other aspects of steroid metabolism, with the consequence that its use is often associated with undesirable side-effects. It is a particular object of the present invention to provide aromatase inhibitory compounds with fewer undesirable side effects than aminoglutethimide.
• United States Patent No. 4,226,878 discloses inter alia compounds similar to those of the present invention, in which R 6 (see formula I below) is imidazolyl and the group R I R 2 R 3 C (equivalent to -(B) m -Y in claim 1 of the US patent) may be -CH 2 COOH or -CH 2 COO(C 2 -7alkyl).
• United States Patent No. 4,271,170 discloses inter alia compounds similar to those of the present invention, in which R 1 (see formula 1 below) is pyridyl and the group R l R 2 R 3 C may be -CH 2 CN (Reference Example 3, column 23).
• EP-A-236 940 discloses inter alia compounds similar to those of the present invention in which the group RlR2R3C- (see formula 1 below) is replaced by a cyano radical.
• Tanouchi et al, J Med Chem, 1981, 24, 1149-115 discloses inter alia the compound in which (referring to formula I below), R 6 is 3-pyridyl, A is ethylene and R 1 R 2 R 3 C is -CH(OH).CH 3 .
• Chem Abstr, 99, 139652b discloses inter alia a compound similar to that of the present invention in which R 6 is 1,2,4-triazol-4-yl, A is methylene and R 1 R 2 R 3 C is -CH(CH).OCO.-(substituted cyclopropane).
• J Org Chem, 1987, 52(5), 946-948 discloses inter alia a compound in which (referring to formula I below) R 6 is imidazolyl, A is methylene, R 1 is hydroxy and R 2 and R 3 are each 4-methoxyphenyl. None of these prior publications makes any reference to the use of the compounds disclosed therein as aromatase inhibitors.
• R 1 is an azido, carbamoyl, cyano, formyl, hydroxy or nitro radical, a 1-6C 1-hydroxyalkyl, alkoxy, alkylcarbamoyl, alkylthio, alkylsulphinyl or alkylsulphonyl radical, a 2- cyanoethyl radical, optionally bearing one to four 1-6C alkyl substituents, or a 2-6C alkanoyl, halogenoalkanoyl, alkanoyloxy, alkanoylamino, dialkylcarbamoyl or alkoxycarbonyl radical; R 2 and R 3 , which may be the same or different, are each a 1-6C alkyl, deuterioalkyl or halogenoalkyl radical; or R l R 2 R 3 C- is a 1,1-
• Suitable values for A, when it is a substituted methylene or ethylene radical are, for example, an ethylidene, propylidene, butylidene, 1- or 2-methylethylene, 1,2-dimethylethylene, dideuteriomethylene, difluoromethylene, hydroxymethylene, cyanomethylene, carbamoylmethylene and 1-hydroxyethylene (in which C-1 of the ethylene is linked to the benzene ring) radicals.
• Suitable pharmaceutically acceptable acid addition salts are, for example, hydrochlorides, hydrobromides, sulphates, nitrates, phosphates and toluene-p-sulphonates.
• a preferred group of compounds of the invention comprises compounds wherein R 1 is a cyano radical, R 5 is a radical of the formula R 1 R 2 R 3 C wherein R 1 is a cyano or hydroxy radical, and R 6 is a 1H-imidazol-1-yl or 1 H-1,2,4-triazol-1-yl radical, and especially preferred are such compounds wherein R 2 and R 3 , both in the group R I R 2 R 3 C and in R 5 , are methyl or trideuteriomethyl radicals and A is a methylene or dideuteriomethylene radical.
• Particular preferred compounds are the compounds described below as Examples 1, 9, 33, 53 and 54, that is respectively 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropiono nitrile), 2,2'-[5-(imidazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropiononitrile), 2-[3-(1-hydroxy-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile, 2,2'-[5-dideuterio(1H-1,2,4-triazol-1-yl)methyl-1,3-phenylene]di(2-trideuteriomethyl-3,3,3-trideuteriopropiononitrile) and 2,2'-[5-dideuterio(1H-1,2,4-triazol-1-yl)-methyl-1,3-phenylene]di(2-methyl
• the compounds of the invention may be manufactured by processes known per se for the manufacture of analogous compounds. Thus, the following processes are provided as further features of this invention, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and A have the meanings defined above, unless otherwise stated:-
• a suitable value for the known displaceable leaving group X is, for example, a halogen atom, for example a chlorine or bromine atom, or an alkylsulphonyloxy or arylsulphonyloxy radical, for example a mesyloxy or tosyloxy radical or a hydroxy radical.
• X is a hydroxy radical
• the process is preferably carried out in trifluoroacetic acid.
• a suitable metal derivative of a heterocyclic compound of the formula R 6 H is an alkali metal derivative, such as sodium 1H-1,2,4-triazole or 3-pyridyl-lithium.
• a suitable known nitrogen protecting group for a nitrogen atom of R 6 H which is intended not to be involved in the reaction with the compound of the formula II is, for example, a trityl radical.
• a trityl protecting group can be readily removed by acid treatment.
• Examples of the use of such a protected heterocyclic compound are Examples 5 and 6 hereafter, in which R 6 H is 4-methyl-1-tritylimidazole, leading to the desired 5-methyl-1-imidazolyl products rather than the undesired 4-methyl-1-imidazolyl isomers.
• the compound of the formula II wherein X is a bromine atom, which is used as starting material in process (a), may be obtained by standard, relatively simple processes involving bromination of an appropriately-substituted alkylbenzene.
• starting materials of the formula II wherein X is chlorine, alkylsulphonyloxy or arylsulphonyloxy may be obtained by conventional procedures.
• X is chlorine
• alkylsulphonyloxy or arylsulphonyloxy may be obtained by conventional procedures.
• methyl 3,5-dimethylbenzoate VIII was brominated with N-bromosuccinimide to form the 3,5-bis(bromomethyl) compound IX, which was converted as described above to the corresponding dinitrile X and alkylated dinitrile XI.
• This compound XI was then reduced, for example with lithium borohydride, to the corresponding alcohol XII, which was then converted either to the starting material of the formula II in which X is chlorine by reaction with thionyl chloride or phosphoryl chloride, or to a starting material of the formula II in which X is an alkylsulphonyloxy or arylsulphonyloxy radical by reaction with an appropriate alkylsulphonyl chloride or arylsulphonyl chloride, for example mesyl chloride or tosyl chloride.
• Starting materials of the formula II bearing other of the defined substituents may be obtained by generally similar processes.
• Starting materials of the formula II wherein X is a hydroxy radical may similarly be made by conventional procedures, for example as described above for a compound of the formula XII.
• Corresponding starting materials wherein A is an alkylated methylene group may be obtained by reacting a methoxycarbonyl compound, such as for example compound XI, with a Grignard reagent, for example methylmagnesium chloride.
• the oxo compound of the formula III used as starting material in process (b) may be obtained by oxidation of the corresponding hydroxyalkyl compound, (for example compound XIII), for example with pyridinium chlorochromate.
• the epoxide of the formula IV, used in process (c), may be obtained by reacting an aldehyde of the formula III with trimethylsulphoxonium iodide in the presence of a base, for example potassium hydroxide.
• a base for example potassium hydroxide.
• the epoxide may be isolated as such, and then reacted with a heterocyclic compound R 6 H, or the epoxide may be formed in situ by reacting the aldehyde of the formula III, trimethylsulphoxonium iodide and the heterocyclic compound R 6 H together in one reaction.
• a suitable dehydrating agent is, for example, trifluoroacetic anhydride.
• a suitable acid for use in the hydrolysis process is, for example, hydrochloric acid or sulphuric acid.
• a suitable acid anhydride is, for example, trifluoroacetic anhydride.
• the reduction in optional process (iv) may be carried out with, for example, a metal hydride reducing agent, for example lithium aluminium hydride or lithium borohydride.
• a metal hydride reducing agent for example lithium aluminium hydride or lithium borohydride.
• a suitable halogenating agent for use in optional processes (v), (x) and (xiii) is, for example, thionyl chloride or phosphoryl chloride.
• a suitable alkali metal cyanide is, for example, potassium cyanide or sodium cyanide.
• the oxidation in optional process (viii) may be carried out using, for example, a derivative of a peracid, for example sodium periodate, peracetic acid or m-chloroperbenzoic acid.
• a derivative of a peracid for example sodium periodate, peracetic acid or m-chloroperbenzoic acid.
• a suitable halogenating agent to obtain fluorine-substituted compound of the invention is, for example, diethylaminosulphur trifluoride.
• the hydrogenation may be carried out over a metal catalyst, for example, palladium, platinum or nickel, at normal temperature and pressure.
• a metal catalyst for example, palladium, platinum or nickel
• oxidation in optional process (xii) may be carried out, for example, with dimethylsulphoxide and oxalyl chloride, Jones's reagent or periodinane.
• the dehydrohalogenation reaction may be carried out with a base, for example, sodium triazole, a sodium (lower alkoxide) or sodium hydroxide.
• a base for example, sodium triazole, a sodium (lower alkoxide) or sodium hydroxide.
• a suitable reducing agent is, for example, sodium borohydride.
• a suitable trialkylsilane is, for example, triethylsilane, in trifluoroacetic acid.
• a suitable halogen substituent is, for example, a bromine atom
• a suitable metal cyanide is, for example, cuprous cyanide.
• Aromatase inhibition may be demonstrated by the following tests:-
• Aromatase inhibitory activity was measured using the enzyme present in the microsomal fraction of human term placenta, as described by Ryan, J. Biol, Chem. 234,268,1959. Enzyme activity was determined by measuring the amount of tritiated water released from 0.5 micromolar (1 ⁇ ,2 ⁇ - 3 H)testosterone after 20 minutes incubation at 37°. The method used was essentially that described by Thomson and Siiteri, J. Biol. Chem. 249,5364,1974 except that testosterone was used in place of androstenedione. Test compounds were dissolved in dimethylsulphoxide (DMSO) then diluted as appropriate to achieve final concentrations of 2, 0.2 or 0.02ag/ml.
• DMSO dimethylsulphoxide
• the reaction was started by the addition of 50 ⁇ l of microsome suspension to 50 ⁇ l of a solution containing substrate (testosterone) and cofactors (NADPH glucose-6-phosphate and glucose-6-phosphate dehydrogenase) and either DMSO alone or a DMSO solution of test compound. Each concentration of test compound was tested in triplicate.
• the reaction was stopped by the addition of 200 ⁇ l of 5% (w/v) suspension of charcoal in 0.5% (w/v) solution of Dextran T70 in water. After 1 hour the charcoal was precipitated by centrifugation and 150 ⁇ l of supernatant removed and the amount of tritiated water present determined using a liquid scintillation counter. The number of counts in supernatant from incubations containing test compound expressed as a percentage of the counts in supernatant from incubations containing only DMSO was taken as the degree of enzyme inhibition achieved by the test compound.
• the compounds of formula I are active at less than 10 ⁇ g/ml (in vitro), and the preferred compounds of the formula I are active at below 0.1 ⁇ g/ml (in vitro) and 1.0 mg/kg (in vivo), and no indication of any toxicity has been seen at these doses.
• a pharmaceutical or veterinary composition which comprises an effective amount of a compound of the formula I together with a pharmaceutically or veterinarily acceptable diluent or carrier.
• composition of the invention may be in a conventional pharmaceutical form suitable for oral administration, for example a tablet, a capsule, an emulsion or an aqueous or oily solution or suspension.
• the composition may contain conventional pharmaceutical excipients, and may be manufactured by conventional pharmaceutical techniques.
• Preferred pharmaceutical or veterinary compositions of the invention are tablets and capsules containing from 0.1 to 100, preferably 0.25 to 25mg. of a compound of the invention.
• the 5-methyl-1,3-phenylene compound used as starting material in the above process may be prepared as follows:-A mixture of 3,5-bis(bromomethyl)toluene (30g), tetrabutylammonium bromide (1g), potassium cyanide (17.6g), dichloromethane (100ml) and water (30ml) was stirred vigorously and heated under reflux for 3h. The mixture was cooled, diluted with water (100ml) and extracted three times with ethyl acetate.
• Example 5 The process described in Example 5 was repeated, using 2,2'-(5-bromomethyl-1,3-phenylene)di(2-methylpropiononitrile) as the starting material, to obtain 2,2'-[5-(5-methylimidazol-1- yl)-1,3-phenylene]di(2-methylpropiononitrile), mp. of hydrochloride salt, 183-185°, crystallised from ethyl acetate.
• the 5-(1-chloroethyl)-1,3-phenylene derivative used as starting material in the above process may be prepared as follows:-A solution of 2,2'-(5-hydroxymethyl-1 ,3-phenylene)di(2-methylpropiononitrile), (1.9g), in dichloromethane (20ml) was treated with pyridinium chlorochromate (2.15g) and stirred at room temperature for 1.5h. The reaction mixture was subjected to flash column chromatography, eluting with dichloromethane, to give 2,2'-(5-formyl-1,3-phenylene)di(2-methylpropiononitrile), mp. 145-147°.
• the chloromethyl compound used as starting material in the above process may be prepared as follows:-A mixture of methyl 3,5-dimethylbenzoate (6g), N-bromosuccinimide (13g), benzoyl peroxide (50mg) and carbon tetrachloride (150ml) was heated under reflux for 1 h. The mixture was then cooled and filtered, the filtrate was evaporated to dryness under reduced pressure, and the residue was crystallised from cyclohexane to give methyl 3,5- bis(bromomethyl)benzoate mp. 99-101 °.
• methyl 3,5-bis(bromomethyl)benzoate was treated with potassium cyanide in a similar manner to that described in the second part of Example I to give methyl 3,5-bis(cyanomethyl)benzoate mp. 90-920, which was then alkylated with methyl iodide as also described in the latter part of Example I, to give methyl 3,5-bis(1-cyano-1-methyl ethyl)benzoate, mp. 83-85°.
• Example 9 The compound of Example 9 was prepared from the chloromethyl starting material described in Example 8; and the compounds of Examples 10-16 were prepared from the corresponding bromomethyl starting materials, made by the sequence of reactions described in the second part of Example 1, and used without further purification.
• Example 8 The process described in Example 8 was repeated, using imidazole in place of 1,2,4-triazole, and 2,2'-[5-(1- chloroethyl)-1,3-phenylene]di(2-methylpropiononitrile), (obtained as described in the second part of Example 7), as the starting materials, to give 2,2'-[5-(1-[imidazol-1-yl]ethyl)-1,3-phenylene]di(2-methylpropiononitrile), mp. 77-800.
• Example 18 The process described in Example 18 was repeated, using as starting material the product of Example 1, to give 2-[3-(1-cyano-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropionamide, (eluted from the flash chromatography column with methanol:ethylacetate, 1:3 by volume), mp. 134-1350°; and 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionamide), mp. 51-53°, eluted from the flash chromatography column with methanol: ethyl acetate, (1:2 by volume).
• Example 16 The product from Example 16 (0.12g) and concentrated aqueous ammonia (3ml) were stirred together at room temperature for 72h. The insoluble product was filtered off, washed with water and dried to give 3-(1-cyano-1-methylethyl)-5-(imidazol-1-ylmethyl)benzamide, mp. 149-150°.
• Example 21 The process described in Example 21 was repeated, using the product of Example 4 as the starting material, to give 3-(1-cyano-1-methylethyl)-5-(1 H-1,2,4-triazol-1-ylmethyl)-benzamide, mp. 144-145°.
• Example 23 The process described in Example 23 was repeated, using the product of Example 21 as the starting material, to give 3-(1-cyano-1-methylethyl)-5-(imidazol-1-ylmethyl)- benzonitrile, mp. 89-92 ° .
• Example 22 The process described in Example 22 was repeated, using piperidine in place of aqueous ammonia, and heating at 80 ° for 72h to give 2-methyl-2-[3-piperidinocarbonyl-5-(1H-1,2,4- triazol-1-ylmethyl]-propiononitrile.
• Nmr in deuteriochloroform, 6 8.2(1 H,s), 8.0(1 H,s), 7.48(1 H,m), 7.44(1 H,m), 7.2(1 H,m), 5.4-(2H,s), 3.68(2H,m), 3.27(2H,m), 1.4-1.8(12H,m).
• Example 25 The process described in Example 25 was repeated, using morpholine in place of piperidine, to give 2-methyl-2-[3-morpholinocarbonyl-5-(1H-1,2,4-triazol-1-ylmethyl]-propiononitrile.
• Nmr in deuteriochloroform, 6 8.18(1 H,s), 8.0(1 H,s), 7.5(1 H,m), 7.45(1 H,m), 7.2(1 H,m), 5.4(2H,s), 3.5-3.9(8H,m), 1.72(6H,s).
• Example 32 The process described in Example 32 was repeated, using the product from Example 4 as the starting material, to give 2-[3-(1-hydroxy-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile, mp. 152-4°, after crystallisation from diethyl ether.
• the required starting material for use in the above process may be manufactured as follows:-
• the 1-hydroxyethyl starting material used in the above process may be manufactured as follows:-
• the formyl compound (0.2g) was dissolved in tetrahydrofuran (1 ml), stirred and cooled to -70 under an atmosphere of argon, and a solution of methylmagnesium chloride in tetrahydrofuran (3m, 0.32ml) was added, The mixture was stirred at -70 for 0.5h and allowed to warm to room temperature, then saturated aqueous ammonium chloride solution (10ml) was added. The mixture was extracted three times with dichloromethane, and the extracts were combined, dried and evaporated to dryness under reduced pressure to give the required 1-hydroxyethyl starting material, which was used without further purification.
• the starting material from the above process may be prepared as follows:-The process used to prepare methyl 3,5-bis(1-cyano-1-methylethyl)benzoate, described in the later part of Example 8, was repeated, using trideuterioiodomethane instead of iodomethane, to give methyl 3,5-bis[1-cyano-2,2,2-trideuterio-1-(trideuteriomethyl)ethyl]benzoate, m.p. 83-84°.
• the starting material for the above process was obtained as follows:-A suspension of ethyl imidazole-4-carboxylate (1.4g), triethylamine (1.2g) and chloroform (20ml) was stirred at room temperature while trityl chloride (3.06g) was added, and the mixture was stirred at room temperature for 1 h. The resulting solution was washed with water, dried and evaporated to dryness under reduced pressure, and the residue was crystallised from a mixture of ethyl acetate and cyclohexane, to give ethyl 1-tritylimidazole-4-carboxylate, mp 163-164 ° .
• the starting material for the above example may be prepared as follows:
• Example 34 The process described in Example 34 was repeated, using 5-bromopyrimidine instead of 3-bromopyridine, and a reaction temperature of -110°, to give 2,2'-[5-hydroxy(5-pyrimidinyl)methyl]-1,3-phenylene]di(2-methylpropiononitrile), mp 129-130°.
• Example 61 The process described in Example 61 was repeated, using 2,2'-[5-(1-hydroxy-1-(5-pyrimidinyl)methyl)-1,3-phenylene]di(2-methylpropiononitrile as starting material, to give 2,2'-[5-fluoro(5-pyrimidinyl)methyl-1,3-phenylene]di(2-methylpropiononitrile, mp 72-740.
• the nicotinoyl compound used as starting material in the above process was obtained as follows:-
• Example 67 The process described in Example 67 was repeated, using imidazole instead of 1,2,4-triazole, to give 2,2'-[5-cyano(imidazol-1-yl)methyl-1,3-phenylene]di(2-methylpropiononitrile), mp 136-138°.

Applications Claiming Priority (2)

Publications (2)

Family

ID=10618970

Family Applications (1)

Country Status (22)

Cited By (1)

Families Citing this family (46)

Family Cites Families (12)

• 1987
  • 1987-06-16 GB GB878714013A patent/GB8714013D0/en active Pending
• 1988
  • 1988-05-19 IE IE150588A patent/IE65570B1/en active Protection Beyond IP Right Term
  • 1988-05-24 ZA ZA883691A patent/ZA883691B/xx unknown
  • 1988-05-25 IL IL86499A patent/IL86499A/xx not_active IP Right Cessation
  • 1988-05-31 AU AU16911/88A patent/AU605872B2/en not_active Expired
  • 1988-06-10 US US07/204,743 patent/US4935437A/en not_active Ceased
  • 1988-06-14 EP EP88305429A patent/EP0296749B1/en not_active Expired - Lifetime
  • 1988-06-14 LU LU88778C patent/LU88778I2/fr unknown
  • 1988-06-14 AT AT88305429T patent/ATE113277T1/de active
  • 1988-06-14 DE DE3851914T patent/DE3851914T2/de not_active Expired - Lifetime
  • 1988-06-14 ES ES88305429T patent/ES2063036T3/es not_active Expired - Lifetime
  • 1988-06-14 PT PT87720A patent/PT87720B/pt not_active IP Right Cessation
  • 1988-06-15 NZ NZ225037A patent/NZ225037A/xx unknown
  • 1988-06-15 NO NO882628A patent/NO170080C/no not_active IP Right Cessation
  • 1988-06-15 CA CA000569512A patent/CA1337420C/en not_active Expired - Lifetime
  • 1988-06-16 JP JP63147068A patent/JP2609290B2/ja not_active Expired - Lifetime
  • 1988-06-16 FI FI882882A patent/FI97804C/fi active Protection Beyond IP Right Term
  • 1988-06-16 DK DK198803304A patent/DK174573B1/da not_active IP Right Cessation
• 1992
  • 1992-06-15 MX MX9202876A patent/MX9202876A/es unknown
• 1995
  • 1995-05-31 HU HU95P/P00144P patent/HU211142A9/hu unknown
• 1996
  • 1996-04-03 US US08/627,311 patent/USRE36617E/en not_active Expired - Lifetime
• 1997
  • 1997-03-04 NL NL970012C patent/NL970012I2/nl unknown
  • 1997-05-16 NO NO1997006C patent/NO1997006I1/no unknown
  • 1997-09-05 HK HK97101733A patent/HK1000206A1/xx not_active IP Right Cessation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events